Your browser doesn't support javascript.
loading
Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans.
Williams, Wilton B; Alam, S Munir; Ofek, Gilad; Erdmann, Nathaniel; Montefiori, David C; Seaman, Michael S; Wagh, Kshitij; Korber, Bette; Edwards, Robert J; Mansouri, Katayoun; Eaton, Amanda; Cain, Derek W; Martin, Mitchell; Hwang, JongIn; Arus-Altuz, Aria; Lu, Xiaozhi; Cai, Fangping; Jamieson, Nolan; Parks, Robert; Barr, Maggie; Foulger, Andrew; Anasti, Kara; Patel, Parth; Sammour, Salam; Parsons, Ruth J; Huang, Xiao; Lindenberger, Jared; Fetics, Susan; Janowska, Katarzyna; Niyongabo, Aurelie; Janus, Benjamin M; Astavans, Anagh; Fox, Christopher B; Mohanty, Ipsita; Evangelous, Tyler; Chen, Yue; Berry, Madison; Kirshner, Helene; Van Itallie, Elizabeth; Saunders, Kevin O; Wiehe, Kevin; Cohen, Kristen W; McElrath, M Juliana; Corey, Lawrence; Acharya, Priyamvada; Walsh, Stephen R; Baden, Lindsey R; Haynes, Barton F.
Afiliação
  • Williams WB; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke School of Medicine, Durham, NC 27710, USA; Department of Integrative Immunobiology, Duke School of Medicine, Durham, NC 27710, USA. Electronic address: wilton.williams@duke.edu.
  • Alam SM; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke School of Medicine, Durham, NC 27710, USA. Electronic address: munir.alam@duke.edu.
  • Ofek G; Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD 20742, USA; Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, USA.
  • Erdmann N; University of Alabama Medical Center, Birmingham, AL 35223, USA.
  • Montefiori DC; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke School of Medicine, Durham, NC 27710, USA.
  • Seaman MS; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Wagh K; Los Alamos National Laboratory, Los Alamos, NM 87545, USA; New Mexico Consortium, Los Alamos, NM 87544, USA.
  • Korber B; Los Alamos National Laboratory, Los Alamos, NM 87545, USA; New Mexico Consortium, Los Alamos, NM 87544, USA.
  • Edwards RJ; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke School of Medicine, Durham, NC 27710, USA.
  • Mansouri K; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Eaton A; Department of Surgery, Duke School of Medicine, Durham, NC 27710, USA.
  • Cain DW; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke School of Medicine, Durham, NC 27710, USA.
  • Martin M; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Hwang J; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Arus-Altuz A; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Lu X; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Cai F; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke School of Medicine, Durham, NC 27710, USA.
  • Jamieson N; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke School of Medicine, Durham, NC 27710, USA.
  • Parks R; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Barr M; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Foulger A; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Anasti K; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Patel P; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Sammour S; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Parsons RJ; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Huang X; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Lindenberger J; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Fetics S; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Janowska K; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Niyongabo A; Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD 20742, USA.
  • Janus BM; Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD 20742, USA; Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, USA.
  • Astavans A; Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD 20742, USA.
  • Fox CB; Access to Advanced Health Institute, Seattle, WA 98102, USA.
  • Mohanty I; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Evangelous T; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Chen Y; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Berry M; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Kirshner H; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Van Itallie E; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
  • Saunders KO; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke School of Medicine, Durham, NC 27710, USA; Department of Integrative Immunobiology, Duke School of Medicine, Durham, NC 27710, USA; Department of Molecular Genetics and Microbiology, Duke School
  • Wiehe K; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke School of Medicine, Durham, NC 27710, USA.
  • Cohen KW; Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
  • McElrath MJ; Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
  • Corey L; Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
  • Acharya P; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke School of Medicine, Durham, NC 27710, USA; Department of Biochemistry, Duke School of Medicine, Durham, NC 27710, USA.
  • Walsh SR; Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: swalsh@bwh.harvard.edu.
  • Baden LR; Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: lbaden@bwh.harvard.edu.
  • Haynes BF; Duke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke School of Medicine, Durham, NC 27710, USA; Department of Integrative Immunobiology, Duke School of Medicine, Durham, NC 27710, USA; Duke Global Health Institute, Duke School of Medicine, Durham
Cell ; 187(12): 2919-2934.e20, 2024 Jun 06.
Article em En | MEDLINE | ID: mdl-38761800
ABSTRACT
A critical roadblock to HIV vaccine development is the inability to induce B cell lineages of broadly neutralizing antibodies (bnAbs) in humans. In people living with HIV-1, bnAbs take years to develop. The HVTN 133 clinical trial studied a peptide/liposome immunogen targeting B cell lineages of HIV-1 envelope (Env) membrane-proximal external region (MPER) bnAbs (NCT03934541). Here, we report MPER peptide-liposome induction of polyclonal HIV-1 B cell lineages of mature bnAbs and their precursors, the most potent of which neutralized 15% of global tier 2 HIV-1 strains and 35% of clade B strains with lineage initiation after the second immunization. Neutralization was enhanced by vaccine selection of improbable mutations that increased antibody binding to gp41 and lipids. This study demonstrates proof of concept for rapid vaccine induction of human B cell lineages with heterologous neutralizing activity and selection of antibody improbable mutations and outlines a path for successful HIV-1 vaccine development.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos B / Anticorpos Anti-HIV / HIV-1 / Vacinas contra a AIDS / Anticorpos Neutralizantes Limite: Humans Idioma: En Revista: Cell Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos B / Anticorpos Anti-HIV / HIV-1 / Vacinas contra a AIDS / Anticorpos Neutralizantes Limite: Humans Idioma: En Revista: Cell Ano de publicação: 2024 Tipo de documento: Article